Carbapenem-resistant Acinetobacter baumannii (CRAB) is a perilous nosocomial pathogen causing substantial morbidity and mortality. Current treatment options for CRAB are limited and suffer from pharmacokinetic limitations such as high toxicity and low plasma levels. As a result, CRAB is declared as the top priority pathogen by the World Health Organization for investment in new drugs. This urgent need for new therapies, in combination with faster FDA approval process accelerated new drug development and placed several drug candidates in the pipeline. This article reviews available information about the new drugs and other therapeutic options focusing on agents in clinical or late stage pre-clinical studies for the treatment of CRAB and evaluates their expected benefits and potential shortcomings.
https://ift.tt/2OV8R7R
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.